Relevant patient characteristics by dosage group
| BSE-SFN dosage group | |||
|---|---|---|---|
| 50 μmol (n = 6) | 100 μmol (n = 6) | 200 μmol (n = 5) | |
| Sex (female) | 3 (50%) | 4 (67%) | 5 (100%) |
| Age (median) | 46 yrs. | 51 yrs. | 44 yrs. |
| Race (Caucasian) | 6 (100%) | 6 (100%) | 5 (100%) |
| Prior melanoma history, by stage | MIS (1) | MIS (1) | Stage I (4) |
| Stage I (4) | Stage I (3) | Stage III (1) | |
| Stage II (2) | Stage III (1) unstageable (1) | ||
Abbreviation: MIS, melanoma in situ.